|
|
Learn about new and evolving IBD study designs and endpoints to help interpret the most recent and exciting Crohn’s and ulcerative colitis clinical trial data.
|
|
|
|
Psoriasis is a chronic and inflammatory skin disease with potential systemic implications that affects 7.5 million people in the United States that can lead to several comorbidities, including psoriatic arthritis, obesity, metabolic syndrome, and cardiovascular disease. Due to ongoing suboptimal management of PsA, there is a need to educate clinicians that treat patients with PsA on the diagnosis and current treatment approach, particularly in light of new guidelines for psoriasis and PsA.
|
|
|
|
This case-based activity features insight from two expert physicians as well as a caregiver of a longtime AD patient to provide 360-degree insight on current and potential future strategies for the management of moderate-to-severe AD.
|
|
|
|
This Journal Club activity provides the goal of improving the health and quality of life for pediatric patients with asthma.
|
|
|
|
.75 CME CE Analyzes data from clinical trials, discusses future therapies, and highlights clinical pearls and how to integrate them into practice. Exp 6/18/22
|
|
|
|
0.50 CME: Reviews evidence for approval of HAS I-131-MIBG and best practices for preparing patients, executing dosimetry and therapy. Exp 11/30/2022
|
|
|
|
Use your organizational skills to solve each Sort-it board by placing tiles in the correct order and category. Learn how to better manage your patients with PAH in this interactive game.
|
|
|
|
Learn how to better manage your patients with PAH while competing against others. Check out this classic game, Jeopardy!
|
|
|
|
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
|
|
|
|
In this symposium, experts will discuss data from recent and ongoing trials of iron repletion in patients with HF to highlight the importance of diagnosis and proper management of this common comorbidity and review recent updates to established HF treatment guidelines that emphasize ID recognition and treatment. Additionally, the program will educate clinicians on the differences in oral versus intravenous iron formulations.
|
|
|
